This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 23/3/475    most recent 01.ATV.0000058860.62870.6Ev1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Argmann, C.A. Articles by Huff, M.W. Search for Related Content PubMed PubMed Citation Articles by Argmann, C.A. Articles by Huff, M.W. Related Collections Coagulation inhibitors Endothelium/vascular type/nitric oxide

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:475.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Activation of Peroxisome Proliferator–Activated Receptor Gamma and Retinoid X Receptor Results in Net Depletion of Cellular Cholesteryl Esters in Macrophages Exposed to Oxidized Lipoproteins

C.A. Argmann; C.G. Sawyez; C.J. McNeil; R.A. Hegele; M.W. Huff

From the Departments of Medicine and Biochemistry and Robarts Research Institute at the University of Western Ontario, London, Ontario, Canada.

Correspondence to M.W. Huff, Robarts Research Institute, Rm 4-16, 100 Perth Dr, London, Ontario, Canada, N6A 5K8. E-mail: mhuff{at}uwo.ca

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Objective— Peroxisome proliferator–activated receptor gamma (PPAR), a ligand-activated transcription factor, has pleiotropic effects, including regulation of macrophage differentiation and lipid homeostasis. The PPAR ligands, thiazolidinediones (TZDs), attenuate atherosclerosis in mice by uncertain mechanisms. The objective of this study was to determine whether activation of PPAR or its obligate heterodimer, retinoid X receptor (RXR), modulates macrophage foam cell formation induced by oxidized (ox) lipoproteins.

Methods and Results— Incubation of THP-1 macrophages with oxHTG-VLDL, oxREM, or oxLDL increased cellular cholesteryl ester over 6-fold. Preincubation with the TZD, ciglitazone, the RXR-specific ligand, 9-cis retinoic acid (9cRA) or the combination reduced CE mass accumulation by up to 65%. Ciglitazone and 9cRA increased CD36 mRNA (up to 4-fold); however, uptake of [¹²⁵I]oxLDL was only modestly enhanced (up to 1.8-fold) becaues of a concomitant PPAR:RXR–induced decrease in SRAI/II activity (up to 40%). This suggested that PPAR:RXR activation inhibited cholesteryl ester accumulation by enhancing cholesterol efflux. Ciglitazone and 9cRA were found to increase the expression of ATP-binding cassette proteins A1 and G1, resulting in enhanced cholesterol efflux to lipoprotein-deficient serum, apoAI and HDL₃.

Conclusions— PPAR and/or RXR activation inhibit foam cell formation through enhanced cholesterol efflux despite increased oxLDL uptake. These observations explain the reduced atherosclerosis in TZD-treated mice and may extend the therapeutic implications of these ligands.

Key Words: macrophages • oxidized lipoproteins • PPAR • atherosclerosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Peroxisome proliferator-activated receptor gamma (PPAR) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. These molecules regulate gene expression by binding to DNA in a heterodimeric complex with another nuclear hormone receptor, retinoid X receptor (RXR).^1,2 Although the function of PPAR is best defined for adipogenesis and glucose homeostasis,³ it is also a key regulator of macrophage function.^4–6 Because PPAR targets genes involved in lipid metabolism, it is also implicated in cholesterol homeostasis.^7,8 PPAR is highly expressed in both macrophages and macrophage-derived foam cells,^9,10 suggesting it plays a role in atherogenesis. Given the widespread clinical use of PPAR ligands to improve insulin sensitivity in type 2 diabetes, it is critical to determine how PPAR regulates macrophage function and foam cell formation.¹¹

PPAR activators include naturally occurring ligands, such as polyunsaturated fatty acids and the prostanoid 15-deoxy-^12,13- prostaglandin J2,³ as well as the insulin-sensitizing drugs known as thiazolidinediones (TZDs).¹² On ligand binding, PPAR undergoes a conformational change, enabling heterodimerization with its obligate partner, RXR. This complex can then bind to a direct repeat consensus sequence or PPAR response element (PPRE) located in the promoter region of target genes.¹⁴ The PPAR:RXR heterodimer can also be activated by an RXR-specific ligand, alone such as 9-cis retinoic acid (9cRA), and when used in combination with a PPAR ligand, the activity of the dimer is enhanced further.¹³

The scavenger receptor, CD36, contains a PPRE in its promoter region and is a target of PPAR activation.⁷ In PPAR-null macrophages, basal expression of CD36 and its stimulation by TZDs was significantly reduced.¹⁵ CD36 mediates a significant proportion of oxidized (ox) lipoprotein uptake in cultured macrophages and in CD36-null mice the development of atherosclerosis was reduced.¹⁶ In addition, a feed-forward loop has been described, whereby macrophage uptake of oxLDL provides ligands for PPAR, including 9-hydroxyoctadecadienoic acid and 15-hydroxyoctadecadi- enoic acid, thereby perpetuating CD36 expression and thus potentially increasing oxLDL uptake.^17,18 Consequently, PPAR activation was predicted to promote macrophage foam cell formation and by extension atherogenesis.

However, PPAR activation by rosiglitazone or troglitazone reduces atherosclerotic lesions in LDL receptor (LDLR)-null^19,20 and apoE–null mice,²¹ despite an increase in macrophage CD36 expression.^19,21 Furthermore, increased lesions were observed in macrophage-specific PPAR-null mice, generated by transplantation of bone marrow from PPAR-null mice to LDLR-null mice.²² One explanation for the protective effect of PPAR activation is that enhanced CD36 expression in adipocytes could provide a relatively benign sink for potentially deleterious oxLDL.²³ Other potential mechanisms have been proposed, including attenuation of hyperinsulinemia and/or hyperglycemia; increase of plasma HDL cholesterol concentration;²¹ and a reduction in adhesion molecules, chemokine receptors, and chemokines, such as monocyte chemotactic protein.^8,20 Still uncertain in these animal models is the role of macrophage foam cell formation in the PPAR-induced inhibition of atherogenesis.

The results of in vitro studies are inconclusive as to whether PPAR activation increases oxLDL uptake.^7,15 In THP-1 macrophages, PPAR and RXR ligands increased CD36 expression, leading to enhanced DiI-labeled oxLDL uptake,⁷ whereas in wild-type embryonic stem cells (ES), [¹²⁵I]oxLDL uptake was unaffected by a PPAR or RXR ligand alone, although a 20% decrease with both ligands together was observed.¹⁵ However, oxLDL uptake does not specifically measure CD36 activity but rather the activity of all scavenger receptors that recognize oxLDL, including SRAI/II. PPAR ligands do not appear to affect SRAI/II mRNA expression; however, protein levels were reduced in troglitazone-treated wild-type ES cells,¹⁵ a result that would predict a decrease in oxLDL uptake. Nevertheless, the impact of PPAR activation on macrophage expression of both CD36 and SRAI/II and how this influences net ox lipoprotein uptake remains to be clearly established. Furthermore, the link between macrophage PPAR activation, oxidized lipoprotein-induced CE accumulation and subsequent foam cell formation has yet to be fully elucidated.

PPAR activators also modulate cholesterol efflux by regulating the gene expression of ATP-binding cassette proteins A1 (ABCA1) and G1 (ABCG1).^22,24,25 The integral role of ABCA1 in regulating cellular cholesterol transport is exemplified by loss-of-function mutations causing Tangier disease, which is characterized by significant cholesterol accumulation in macrophages.^26,27 ABCA1 expression is upregulated by PPAR ligands through a transcriptional cascade mediated by the nuclear hormone receptor, liver X receptor (LXR).²² The LXR gene contains a PPRE, so that on PPAR activation, LXR expression is induced. Ligand-bound LXR heterodimerizes with RXR and binds the LXRRE in the ABCA1 promoter, thereby increasing its expression and enhancing cellular cholesterol efflux to HDL and apoAI. PPAR activation in macrophages stimulates ABCA1 expression and promotes cholesterol efflux from lipid-loaded cells, a result that has been confirmed by the lack of effect of PPAR ligands in PPAR-null cells.²⁵ Thus, the overall consequence of PPAR ligands on macrophage cholesteryl ester (CE) accumulation and hence foam cell formation would be the net effect on the competing processes of lipoprotein uptake and cholesterol efflux.

Therefore, our objectives were to examine the impact of PPAR and/or RXR ligands on cellular cholesterol accumulation induced by ox lipoproteins in cultured macrophages and to elucidate the mechanisms involved. Our results demonstrate that macrophage CE accumulation induced by ox lipoproteins is significantly reduced by TZDs. In addition, the RXR ligand, 9cRA, reduced CE accumulation, and this effect was amplified when combined with ciglitazone. Ciglitazone alone or in combination with 9cRA significantly enhanced both expression of ABCA1 and ABCG1 and efflux of cholesterol to lipoprotein-deficient serum (LPDS) apoAI and HDL₃. Despite a marked induction in CD36 expression, uptake of [¹²⁵I]oxLDL was only modestly increased. This was caused by a decrease in SRAI/II activity by PPAR and RXR ligands. On balance, PPAR and RXR activation reduces the CE accumulation in macrophages induced by ox lipoproteins as the result of an overriding impact on ABCA1-mediated cholesterol efflux.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Please see online data supplement (which can be accessed at http://atvb.ahajournals.org) for materials and methods.

	Results

Top Abstract Introduction Methods Results Discussion References

 
OxHTG
VLDL and their remnants induced lipid accumulation in THP-1 human macrophages: Incubation of THP-1 human macrophages with oxHTG-VLDL and oxREM induced CE mass by 6.2- and 6.4-fold (both P<0.05) and triglyceride (TG) mass by 2.7- and 3.0-fold (both P<0.05), respectively (Figure 1A and B). Similarly, oxLDL and AcLDL induced cellular CE accumulation by 5.8- and 11-fold (P<0.05), with neither lipoprotein inducing TG mass accumulation. Cellular free cholesterol (FC) mass was significantly enhanced by all modified lipoprotein preparations (1.5- to 2.2-fold; Figure 1C), a result consistent with the observation that cholesterol derived from ox lipoproteins is retained within the lysosomal compartment for an extended period.²⁸

View larger version (42K): [in this window] [in a new window]   Figure 1. The effect of ciglitazone (Cig) and 9cRA on macrophage cellular lipid mass accumulation induced by modified lipoproteins is shown. THP-1 macrophages were preincubated with ciglitazone (25 µmol/L) or 9cRA (10 nmol/L) alone or in combination for 24 h before the re-addition of drugs in the absence or presence of modified lipoprotein. Human oxHTG-VLDL and oxREM were added at a concentration of 50 µg lipoprotein total cholesterol/mL medium and the modified LDL concentration used was 150 µg lipoprotein total cholesterol/mL medium. CE (A), TG (B), and FC (C) mass content was measured in cells as described in the Methods section. Control indicates lipid mass in the absence of lipoproteins. Values are expressed as mean±SEM (n=4), where *P<0.05 compared with control and P<0.05 compared with lipoprotein alone.

Ligand Activation of PPAR Inhibited CE Mass Induced by Modified Lipoproteins
Pretreatment of THP-1 macrophages with ciglitazone significantly inhibited cellular CE mass induced by oxHTG-VLDL, oxREM, or oxLDL by -40%, -38%, and -47% (all, P<0.05), respectively, compared with lipoprotein alone (Figure 1A). The effect of ciglitazone on CE mass was dose dependent (Figure 2). In addition, another TZD, troglitazone, inhibited cellular CE accumulation induced by oxHTG-VLDL in a dose-dependent manner from -42% to -68% (P<0.05; Figure 2).

View larger version (47K): [in this window] [in a new window]   Figure 2. The dose-dependent effect of PPAR and RXR ligands on macrophage cellular CE accumulation induced by oxHTG-VLDL. THP-1 macrophages were treated with either ciglitazone, troglitazone, or 9cRA at varying concentrations for 24 h before the addition of oxHTG-VLDL (50 µg lipoprotein total cholesterol/mL medium) for an additional 16 h. CE mass was measured as described in the Methods section. Values represent mean±SEM, expressed as percent of control (n=3), where *P<0.05 relative to incubation with lipoprotein alone.

In contrast, TG mass induced by either lipoprotein preparation was unaffected by pretreatment of cells with either TZD (Figure 1B and data not shown). Also, in the absence of ox lipoprotein the TZDs had no significant effect on cellular CE content.

Ligand Activation of RXR Inhibited CE Mass Induced by Modified Lipoproteins
Pretreatment of macrophages with 9cRA significantly inhibited oxHTG-VLDL-, oxREM-, and oxLDL-induced CE mass by -36%, -33%, and -44% (all P<0.05), respectively, compared with lipoprotein alone (Figure 1A). The effect of 9cRA was dose dependent, with inhibition of CE mass induced by oxHTG-VLDL ranging from -15% to -50% (P<0.05, Figure 2). In contrast, 9cRA did not affect TG mass induced by any ox lipoproteins tested (Figure 1B).

Combined RXR and PPAR Activation Markedly Reduced CE Accumulation Induced by Ox Lipoproteins
To further enhance the activity of the PPAR:RXR heterodimer, THP-1 cells were pretreated with ciglitazone and 9cRA together. These ligands significantly reduced CE accumulation induced by oxHTG-VLDL, oxREM, or oxLDL by -69%, -52% and -63% (all P<0.05, Figure 1A), respectively, compared with lipoprotein alone. This decrease in CE mass was markedly enhanced compared with the inhibition observed by either PPAR or RXR ligand alone, suggesting a synergistic effect. In contrast, TG accumulation induced by ox lipoproteins was unaffected by the combination of ligands (Figure 1B).

In addition, the increases in FC mass induced by ox lipoproteins alone were significantly reduced by pretreatment of macrophages with both ciglitazone and 9cRA to levels similar to those observed in control cells (Figure 1C).

PPAR and RXR Activation Inhibited oxHTG-VLDL–Induced CE Accumulation in LDLR-Null and Wild-Type MPMs
TZD treatment of LDLR-null mice inhibits formation of early atherosclerotic lesions in vivo.^19,20 To determine whether this decrease in atherosclerosis may be mediated through a PPAR-induced inhibition of macrophage foam cell formation, MPMs were isolated from both LDLR-null and wild-type mice. OxHTG-VLDL induced CE accumulation in both wild-type and LDLR-null MPMs by approximately 20-fold. Pretreatment of MPMs with ciglitazone significantly inhibited CE accumulation induced by oxHTG-VLDL by -35% and -20% in wild-type and LDLR-null MPMs, respectively (both P<0.05; see online Figure I, which can be accessed at http://atvb.ahajournals.org). Preincubation with 9cRA also significantly inhibited oxHTG-VLDL–induced CE accumulation in both wild-type and LDLR-null MPMs by 23% and 27%, respectively (P<0.05). The concentration of 9cRA required to achieve this effect was higher than that used in THP-1 cells. This was most likely caused by the low level of expression of PPAR in nonthioglycollate-stimulated MPMs. The addition of both ciglitazone and 9cRA together did not further reduce CE accumulation in either cell type.

PPAR and RXR Activation Regulate CD36 and SRAI/II Activity
Macrophage uptake of oxHTG-VLDL is mediated by both CD36 and SRAI/II.^29,30 As demonstrated in the Table, CD36 mRNA was increased 2-fold by either ciglitazone or 9cRA alone and 4-fold by the combination of ligands. Consequently [¹²⁵I]oxLDL binding, uptake, and degradation was increased by 1.3 to 1.8-fold (P<0.05; Figure 3) in cells treated with ciglitazone and 9cRA either alone or in combination. However, this enhanced oxLDL uptake was attenuated compared with the extent of PPAR and RXR-induced CD36 mRNA upregulation. This is because oxLDL is also a ligand for SRAI/II as confirmed by the attenuated increase in CE accumulation induced by oxHTG-VLDL in MPMs from SRAI/II-null (12-fold) mice versus the wild-type MPMs (18-fold; Figure I).³⁰ Therefore, we determined the contribution of SRAI/II expression to the PPAR-mediated decrease in CE accumulation induced by ox lipoproteins by isolating MPMs from SRAI/II-null mice and their controls and pretreating them with PPAR ligands.

View this table: [in this window] [in a new window]   Table 1. The Effect of PPAR and RXR Activation on mRNA Abundance of ABCA1, ABCG1, and CD36 in THP-1 Macrophages

View larger version (31K): [in this window] [in a new window]   Figure 3. Effect of PPAR and RXR activation on SRAI/II and CD36 activity as measured by changes in [125I]oxLDL or [125I]AcLDL binding, uptake and degradation in THP-1 macrophages. Cells were preincubated with ciglitazone (Cig, 25 µmol/L) and/or 9cRA (10 nmol/L) for 24 h and then the total [125 I] modified LDL (5 µg/mL medium) cell associated (binding plus uptake) and degraded at 37°C (n=3) was measured as described in the Methods section. Values represent mean±SEM expressed as a percent of control and the absolute values are as follows: [125I]oxLDL binding and uptake = 290±47.5 ng/mg cell protein; degradation = 360.0±80.8ng/mg cell protein and [125I]AcLDL binding and uptake = 391.3±107.0 ng/mg cell protein; degradation = 719.0±199.6 ng/mg cell protein). *P<0.05 relative to incubation in the absence of drug.

In control cells, ciglitazone and 9cRA alone or in combination significantly inhibited oxHTG-VLDL–induced CE accumulation by -27% to -36% (P<0.05, Figure I). However, in the absence of SRAI/II expression, these ligands alone or in combination, only reduced CE accumulation induced by oxHTG-VLDL by -15% to -22% (P<0.05). Therefore, decreased SRAI/II activity mediates, in part, the reduction in CE mass induced by PPAR and RXR ligands.

Consistent with these findings is the effect of PPAR and RXR ligands on cellular uptake of [¹²⁵I]AcLDL, a modified lipoprotein with ligand specificity for SRAI/II. In THP-1 cells, [¹²⁵I]AcLDL binding, uptake, and degradation were significantly inhibited by ciglitazone by -35% and -24%, respectively (P<0.05; Figure 3). In addition, 9cRA inhibited [¹²⁵I]AcLDL binding, uptake and degradation by -23% and -21%, respectively (P<0.05), an effect slightly enhanced by combining the ligands. This result explains the modest increase in oxLDL uptake in that the increased CD36 expression is offset by a decrease in SRAI/II activity. Furthermore AcLDL-induced cellular CE accumulation in THP-1 cells was significantly inhibited by ciglitazone and 9cRA alone or in combination by -40% to -70% (P<0.05, Figure 1). Collectively these finding indicate that decreased SRAI/II activity contributes to the inhibition of foam cell formation induced by ligands for PPAR and RXR.

PPAR and RXR Activation Enhanced Macrophage Cholesterol Transport Genes and Efflux
Although ciglitazone and 9cRA increased ox lipoprotein uptake, CE mass accumulation induced by these lipoproteins was significantly reduced by both ligands. Therefore, we addressed the effects of PPAR and RXR activation on cholesterol efflux.

ABCA1 and ABCG1 transporters are responsible for the removal of cellular cholesterol stores. Preincubation of macrophages with ciglitazone induced ABCA1 and ABCG1 mRNA expression by 1.7- and 1.8-fold (P<0.05; Table), respectively. Similarly 9cRA induced ABCA1 and ABCG1 expression (1.4-fold for both; P<0.05). Consistent with changes in ABC mRNA expression, pretreatment of cells with ciglitazone or 9cRA significantly increased cholesterol efflux to apoAI by 1.3-fold (P<0.05 for both; Figure 4A). The combination of ciglitazone and 9cRA increased cholesterol efflux by a further 40%. Ciglitazone and 9cRA produced similar increases in cholesterol efflux to HDL₃. Because the lipoprotein-induced CE accumulation experiments were performed in DMEM containing only LPDS, we determined whether these ligands could stimulate cholesterol efflux to LPDS, which contains apoAI. As shown in Figure 4A, addition of LPDS to the media increased efflux to cholesterol by 3-fold (P<0.05) over BSA alone. Importantly, ciglitazone or 9cRA alone further increased cellular cholesterol efflux to LPDS by 23% and 11%, respectively (both P<0.05). Ciglitazone plus 9cRA increased efflux to LPDS by an additional 20%. Thus, enhanced cholesterol efflux is part of the mechanism whereby these ligands block macrophage foam cell formation.

View larger version (49K): [in this window] [in a new window]   Figure 4. PPAR, RXR, and LXR regulation of macrophage cholesterol efflux. Cholesterol-loaded THP-1 macrophages were preincubated with (A) ciglitazone (25 µmol/L, Cig) and/or 9cRA (10 nmol/L) for 24 h (0.2% BSA in RPMI) before incubation of cells with BSA (0.2%) and a cholesterol acceptor, including either apoAI (10 µg/mL), LPDS (5%), or HDL3 (100 µg/mL media) for 24 h or (B) preincubated with ciglitazone and/or 9cRA in the absence or presence of BADGE (10 µmol/L, PPAR antagonist) and/or ECHS (5 µmol/L, LXR antagonist) for 24 h before incubation with apoAI for 24 h. Cholesterol efflux was measured as described in the Methods section and expressed as the percentage of [3H] cholesterol counts in the media vs total [3H] cholesterol counts (media plus cell). Values represent mean±SEM and *P<0.05 compared with BSA, P<0.05 relative to cholesterol acceptor alone and P<0.05 compared with apoAI plus drug (n=3).

Ciglitazone and 9cRA–Mediated Induction of Cholesterol Efflux Is Mediated Through PPAR and LXR
To demonstrate directly that ciglitazone and 9cRA mediate cholesterol efflux through activation of PPAR and subsequently LXR, the effects of known antagonists of PPAR (bisphenol A diglycidyl ether; BADGE)³¹ and LXR (5,6-epoxycholesterol-3-sulfate, ECHS)³² were examined in the cholesterol efflux assay. Incubation of macrophages with BADGE alone had no significant effect on cholesterol efflux to apoAI (Figure 4B). However, co-incubation of BADGE and ciglitazone completely blocked the ciglitazone-induced 30% increase in cholesterol efflux to apoAI. In contrast, the co-incubation of BADGE and 9cRA had no effect on the 9cRA-induced increase in cholesterol efflux to apoAI, suggesting that 9cRA enhances efflux through a mechanism independent of PPAR. Therefore, when cells were incubated with ciglitazone, 9cRA, and BADGE, the amount of cholesterol efflux to apoAI was reduced by 18% (P<0.05), a value similar to that observed in the presence of 9cRA alone plus BADGE.

In contrast with BADGE, the incubation of macrophages with the LXR antagonist (ECHS) alone showed a significant 20% decrease in cholesterol efflux to apoAI (Figure 4B). This result is most likely because of the inhibition of the effects of endogenous LXR ligands. Co-incubation of cells with ciglitazone and ECHS completely blocked the 30% induction of cholesterol efflux to apoAI by ciglitazone. This finding indicates that stimulation of macrophage cholesterol efflux by PPAR activation occurs through LXR. ECHS also completely blocked the enhancement of cholesterol efflux to apoAI induced by 9cRA alone or in combination with ciglitazone, suggesting that 9cRA increases cholesterol efflux through stimulation of the LXR:RXR dimer. The combination of BADGE and ECHS in the presence of either ligand alone or together did not further reduce cholesterol efflux to ECHS alone. Therefore, PPAR and RXR ligands mediate enhanced cholesterol efflux to apoAI through a PPAR:RXR-sensitive pathway.

To further demonstrate the importance of the PPAR:LXR:ABCA1 pathway on foam cell formation, we also used the LXR antagonist in the lipid mass assay. As shown in Figure 5, ECHS completely blocked the ciglitazone- and 9cRA-induced reduction in CE mass in macrophages incubated with oxHTG-VLDL. This suggests that the primary pathway mediating the PPAR inhibition in CE accumulation induced by ox lipoproteins is enhancement of cholesterol efflux through a PPAR:LXR:ABCA1 transcriptional cascade.

View larger version (36K): [in this window] [in a new window]   Figure 5. Role of the PPAR:LXR:ABCA1 pathway in the ciglitazone-induced inhibition of cellular CE mass induced by oxHTG-VLDL in THP-1 macrophages. Macrophages were preincubated with or without ciglitazone (Cig, 25 µmol/L) or 9cRA (10 nmol/L) in the absence or presence of the LXR antagonist, ECHS, for 24 h before the re-addition of drugs in the presence or absence of oxHTG-VLDL (50 µg lipoprotein total cholesterol/mL medium). CE mass was measured as described in the Methods section. Values represent mean±SEM and are expressed as percent of control (n=3). *P<0.05 compared with oxHTG-VLDL alone and P<0.05 relative to oxHTG-VLDL plus LXR antagonist.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In this report we demonstrate that PPAR ligands, namely the TZDs troglitazone and ciglitazone, and an RXR ligand, namely 9cRA, significantly reduced macrophage CE accumulation induced by atherogenic lipoproteins, namely ox-HTG-VLDL, their remnants, and LDL. To our knowledge this is the first report to demonstrate that PPAR and RXR ligands alone or in combination markedly decrease macrophage CE accumulation, thereby inhibiting foam cell formation in vitro. Our findings support a mechanism whereby PPAR and RXR ligands enhance ABCA1- and ABCG1-mediated cellular cholesterol efflux, more than compensating for any increase in the cellular cholesterol pool as a result of increased CD36 scavenger receptor expression and ox lipoprotein uptake.

Since the discovery that PPAR ligands upregulate CD36 expression,⁷ there has been great interest as to whether this leads to enhanced foam cell formation, especially because TZDs are widely prescribed to diabetic patients, a population at high risk of atherosclerosis.¹¹ However, because of inconsistent reports on oxLDL uptake and uncertainty regarding effects on cholesterol efflux,^7,15,24,25 the outcome of ciglitazone and 9cRA treatment on lipoprotein-induced cholesterol mass accumulation in macrophages was difficult to predict. However, it was evident from in vivo mouse studies that PPAR and RXR ligands decrease atherosclerotic lesion formation.^{19–21,25,33} In this study, we show only a modest enhancement in macrophage [¹²⁵I]oxLDL uptake induced by ciglitazone and 9cRA treatment, a finding consistent with Tontonoz et al.⁷ However, Moore et al¹⁵ described a decrease in [¹²⁵I]oxLDL binding, in ES cells treated with troglitazone and LG268. The reasons for these disparities are not readily apparent; however, ES cells may not faithfully reflect either qualitatively or quantitatively the expression of key genes involved in macrophage lipid homeostasis.²⁵ Furthermore, differences in lipoprotein preparation and the extent of oxidation may affect the affinity of oxLDL for various scavenger receptors.³⁴ Using our preparation of ox lipoproteins we have previously demonstrated in SRAI/II-null MPMs that SRAI/II contributes to only 30% of the overall increase in ox lipoprotein-induced CE mass accumulation.³⁰ This implies that in our studies, CD36 is the major scavenger receptor for ox lipoproteins and hence the reason we observe a net increase in [¹²⁵I]oxLDL uptake in the face of the PPAR-induced decrease in SRAI/II activity. Nevertheless, despite the increase in ox lipoprotein uptake, PPAR ligands significantly decrease macrophage CE accumulation induced by ox lipoproteins and hence foam cell formation. Therefore, ox lipoprotein uptake alone can be a poor predictor of macrophage CE accumulation or by extension foam cell formation.

Our results showing inhibition in modified LDL-induced CE accumulation by TZDs differ from the findings of Chinetti et al.²⁴ Those authors demonstrated that in THP-1 macrophages and human primary macrophages, rosiglitazone treatment did not affect cholesterol accumulation induced by AcLDL or oxLDL. It is unclear whether this difference is attributable to rosiglitazone use rather than ciglitazone or troglitazone or to some other mechanism. This lack of effect of rosiglitazone on oxLDL- and AcLDL-induced macrophage cholesterol accumulation is surprising, because in separate experiments, ABCA1 expression and apoAI-mediated cholesterol efflux from cholesterol-loaded cells were significantly increased, a result that concurs with our findings. The possible absence of a cholesterol acceptor in the culture medium could have prevented cholesterol efflux during incubations of macrophages with AcLDL or oxLDL.²⁴ In the present study incubations of macrophages with either oxLDL or AcLDL included LPDS, which we have previously demonstrated to be an effective acceptor of cellular cholesterol.³⁰

In addition to modulating scavenger receptor expression, PPAR and RXR are important regulators of macrophage cholesterol efflux.^24,25,35 Cholesterol efflux to acceptors is mediated by both specific energy-requiring processes and nonspecific passive diffusion.³⁶ Our results clearly demonstrate that ciglitazone and 9cRA, either alone or in combination, can stimulate the expression of both ABCA1 and ABCG1, resulting in enhanced efflux of cellular cholesterol to apoAI and HDL₃. A key observation of this study was that ciglitazone and 9cRA enhanced cholesterol efflux to LPDS. This likely explains the inhibition of CE accumulation in THP-1 and MPMs incubated with ox lipoproteins. Despite enhanced ox lipoprotein uptake with increased CD36 expression, more cholesterol was being effluxed to LPDS (probably because of its content of apoAI³⁰), in response to ciglitazone and 9cRA. Our results agree with those of others who demonstrated that rosiglitazone alone or in combination with the RXR ligand LG268 stimulated expression of ABCA1 and ABCG1 and cholesterol efflux to apoAI from THP-1 cells, MPMs, or human monocyte–derived macrophages.^22,24 However, those authors did not demonstrate that this specifically decreases ox lipoprotein-induced cellular CE accumulation. Our findings contrast those of Akiyama et al,²⁵ who found that in thioglycollate-elicited MPMs, troglitazone decreased the expression of ABCA1 and reduced cholesterol efflux to HDL. Furthermore, those authors showed that, unexpectedly, ciglitazone, rosiglitazone, and pioglitazone had no effect on ABCA1 expression.²⁵ Reasons for such disparities between studies are not readily apparent but may be related to cell type. Again, the effect of these TZDs on foam cell formation was not directly determined.

Several lines of experimental evidence have shown that PPAR regulates ABCA1 and ABCG1 expression through a transcriptional cascade involving LXR.^22,25 We wanted to demonstrate that this cascade applied to THP-1 cells and, importantly, to establish that ABCA1/ABCG1- mediated cholesterol efflux was the predominant mechanism underlying reduced foam cell formation. By using antagonists for both PPAR and LXR,^31,32 we showed that either antagonist completely blocks ciglitazone-enhanced cholesterol efflux to apoAI. This confirms that PPAR activation of ABCA1-mediated cholesterol efflux requires LXR. However, the PPAR antagonist could not inhibit the effect of 9cRA. Macrophage ABCA1 expression is upregulated by both PPAR and LXR agonists (Table).^24,37 However, RXR is the obligate partner for both PPAR and LXR. Therefore, it was not known whether 9cRA mediated enhanced cholesterol efflux to apoAI through activation of the PPAR or LXR dimer. Our results demonstrate conclusively that the 9cRA-induced increase in cholesterol efflux to apoAI was specific to the LXR antagonist, indicating that RXR ligands enhance efflux primarily through an LXR sensitive pathway. Evidence that the PPAR:LXR:ABCA1 pathway regulates foam cell formation in vitro comes from demonstrating the reversal of the ciglitazone-induced CE mass reduction by an LXR antagonist (Figure 5).

Our observation that PPAR and RXR ligands can inhibit foam cell formation induced by ox lipoproteins specifies an important mechanism underlying the reduced atherosclerosis in mice treated with TZDs or RXR ligands.^20,21,33 Although PPAR and RXR ligands tend to stimulate lipoprotein uptake, their ability to stimulate ABCA1- and ABCG1-mediated cholesterol efflux predominates in our macrophage model. These observations imply that the normal physiological response of arterial wall macrophages to PPAR ligands derived from ox lipoproteins is to increase CD36-mediated uptake of these lipoproteins, thereby relieving the arterial wall of the immunological pressure induced by ox lipoproteins. Simultaneously, this would fuel a mechanism whereby the excess intracellular cholesterol is redirected for efflux. In this case, cholesterol esterification would only be stimulated as a protective effect when cholesterol efflux pathways were saturated.³⁸ Nonetheless, our study demonstrates that the addition of exogenous PPAR and/or RXR ligands over and above those ligands derived from oxidized lipoproteins would further stimulate cholesterol efflux through the reverse cholesterol transport pathway. Ultimately, this mechanism would contribute to a reduction in atherogenesis.

	Acknowledgments

 
This work was supported by a Canadian Institute for Health Research grant (FRN/NRF-8014) to M.W.H. C.A.A. is a recipient of a Canadian Institutes for Health Research Studentship. R.A.H. and M.W.H. are Career Investigators of the Heart and Stroke Foundation of Ontario. We are grateful to Allison Kulchycki and Jane Edwards for their expert technical assistance.

Received November 22, 2002; accepted January 15, 2003.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J Mol Med. 2002; 80: 271–281.[CrossRef][Medline] [Order article via Infotrieve]

2. Fruchart J-C, Staels B, Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res. 2001; 44: 345–352.[CrossRef][Medline] [Order article via Infotrieve]

3. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy- 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR . Cell. 1995; 83: 803–812.[CrossRef][Medline] [Order article via Infotrieve]

4. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation. Nature. 1998; 391: 79–82.[CrossRef][Medline] [Order article via Infotrieve]

5. Clark RB. The role of PPARs in inflammation and immunity. J Leukocyte Biol. 2002; 71: 388–400.[Abstract/Free Full Text]

6. Jiang C, Ting AT, Seed B. PPAR- agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998; 391: 82–86.[CrossRef][Medline] [Order article via Infotrieve]

7. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998; 93: 241–252.[CrossRef][Medline] [Order article via Infotrieve]

8. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart J-C, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atheroslcerosis. Arterioscler Thromb Vasc Biol. 2002; 22: 717–726.[Abstract/Free Full Text]

9. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor (PPAR) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998; 95: 7614–7619.[Abstract/Free Full Text]

10. Marx J, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR. Differentiation-dependent peroxisomal proliferator-activated (PPAR) expression and reduction of MMP-9 activity through PPAR activation in mononuclear phagocytes in vitro. Am J Pathol. 1998; 153: 17–23.[Abstract/Free Full Text]

11. Torra IP, Chinetti G, Duval C, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipid. 2001; 12: 245–254.[CrossRef][Medline] [Order article via Infotrieve]

12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazoldinedione is a high affinity ligand for peroxisome proliferator-activated receptors. J Biol Chem. 1995; 270: 12953–12956.[Abstract/Free Full Text]

13. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 1992; 358: 771–774.[CrossRef][Medline] [Order article via Infotrieve]

14. Escher P, Whali W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res. 2000; 448: 121–138.[Medline] [Order article via Infotrieve]

15. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR- in macrophage differentiation and cholesterol uptake. Nat Med. 2001; 7: 41–47.[CrossRef][Medline] [Order article via Infotrieve]

16. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000; 105: 1049–1056.[Medline] [Order article via Infotrieve]

17. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR. J Lipid Res. 2000; 41: 688–696.[Abstract/Free Full Text]

18. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR. Cell. 1998; 82: 229–240.

19. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106: 629–631.[Medline] [Order article via Infotrieve]

20. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 365–371.[Abstract/Free Full Text]

21. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki G, Yahagi N, Iizuka Y, Shionoiri G, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2001; 21: 372–377.[Abstract/Free Full Text]

22. Chawla A, Boisvert WA, Lee C, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001; 7: 161–171.[CrossRef][Medline] [Order article via Infotrieve]

23. Spiegelman BM. PPAR in monocytes: less pain, any gain? Cell. 1998; 93: 153–155.[CrossRef][Medline] [Order article via Infotrieve]

24. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart J-C, Clavey V, Staels B. PPAR and PPAR- activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001; 7: 53–58.[CrossRef][Medline] [Order article via Infotrieve]

25. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1 and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002; 22: 2607–2619.[Abstract/Free Full Text]

26. Orsó E, Broccardo C, Kaminski WE, Böttcher A, Liebisch G, Drobnik W, Götz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani M, Rothe G, Lackner KJ, Chimini G, Schmitz G. Transport of lipids from golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat Genet. 2000; 24: 192–196.[CrossRef][Medline] [Order article via Infotrieve]

27. Lawn RM, Wade DP, Garvin MR, Wang X, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999; 104: R25–R31.

28. Yancey PG, Jerome WG. Lysosomal sequestration of free and esterified cholesterol from oxidized low density lipoprotein in macrophages of different species. J Lipid Res. 1998; 39: 1349–1361.[Abstract/Free Full Text]

29. Lougheed M, Ming Lum C, Ling W, Suzuki H, Kodama T, Steinbrecher UP. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem. 1997; 272: 12938–12944.[Abstract/Free Full Text]

30. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, Huff MW. Transforming growth factor-ß1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol. 2001; 21: 2011–2018.[Abstract/Free Full Text]

31. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. A synthetic antagonist for the peroxisome proliferator-activated receptor inhibits adipocyte differentiation. J Biol Chem. 2000; 275: 1873–1877.[Abstract/Free Full Text]

32. Song C, Hiipakka RA, Liao S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids. 2001; 66: 473–479.[CrossRef][Medline] [Order article via Infotrieve]

33. Claudel T, Leibowitz MD, Fiévet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro J, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction in atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A. 2001; 98: 2610–2615.[Abstract/Free Full Text]

34. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002: in press.

35. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000; 289: 1524–1529.[Abstract/Free Full Text]

36. Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001; 42: 1513–1520.[Abstract/Free Full Text]

37. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent activation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000; 275: 28240–28245.[Abstract/Free Full Text]

38. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002; 8: 1235–1242.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				L.-s. Jiang, J. Pu, Z.-h. Han, L.-h. Hu, and B. He Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages Cardiovasc Res, March 1, 2009; 81(4): 805 - 813. [Abstract] [Full Text] [PDF]

				E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels Regulation of Macrophage Functions by PPAR-{alpha}, PPAR-{gamma}, and LXRs in Mice and Men Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1050 - 1059. [Abstract] [Full Text] [PDF]

				M. M. Beyea, C. L. Heslop, C. G. Sawyez, J. Y. Edwards, J. G. Markle, R. A. Hegele, and M. W. Huff Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol J. Biol. Chem., February 23, 2007; 282(8): 5207 - 5216. [Abstract] [Full Text] [PDF]

				V. Marcil, E. Delvin, A. T. Sane, A. Tremblay, and E. Levy Oxidative stress influences cholesterol efflux in THP-1 macrophages: Role of ATP-binding cassette A1 and nuclear factors Cardiovasc Res, December 1, 2006; 72(3): 473 - 482. [Abstract] [Full Text] [PDF]

				M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]

				J. P. Conway and M. Kinter Proteomic and Transcriptomic Analyses of Macrophages with an Increased Resistance to Oxidized Low Density Lipoprotein (oxLDL)-induced Cytotoxicity Generated by Chronic Exposure to oxLDL Mol. Cell. Proteomics, October 1, 2005; 4(10): 1522 - 1540. [Abstract] [Full Text] [PDF]

				C. A. Argmann, J. Y. Edwards, C. G. Sawyez, C. H. O'Neil, R. A. Hegele, J. G. Pickering, and M. W. Huff Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition: A ROLE FOR RhoA IN ABCA1-MEDIATED CHOLESTEROL EFFLUX J. Biol. Chem., June 10, 2005; 280(23): 22212 - 22221. [Abstract] [Full Text] [PDF]

				K. Z. Al-Shali, A. A. House, A. J.G. Hanley, H. M.R. Khan, S. B. Harris, B. Zinman, M. Mamakeesick, A. Fenster, J. D. Spence, and R. A. Hegele Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor {gamma} Associated With Carotid Atherosclerosis Stroke, September 1, 2004; 35(9): 2036 - 2040. [Abstract] [Full Text] [PDF]

				N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 23/3/475    most recent 01.ATV.0000058860.62870.6Ev1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Argmann, C.A. Articles by Huff, M.W. Search for Related Content PubMed PubMed Citation Articles by Argmann, C.A. Articles by Huff, M.W. Related Collections Coagulation inhibitors Endothelium/vascular type/nitric oxide